Latest

Jul 17, 2026, 18:44 Arvind Krishna Rebuilt IBM Around Software. Now He Has to Make the AI Stack Outrun the Mainframe Cycle

Jul 17, 2026, 16:45 Nikhil Kamath Turned Market Access Into a Media Platform. Influence Now Needs Clearer Boundaries

Jul 17, 2026, 13:40 Lucy Guo Built Passes Around Creator Ownership. Trust Must Become the Subscription Advantage

Jul 17, 2026, 10:35 Shashank Kumar Is Rewiring Razorpay Around Payment Success. Reliability Has to Pay

Jul 16, 2026, 16:45 Ritesh Agarwal Has Taken PRISM Back to the IPO Gate. Investors Will Price the Quality of OYO's Profit

Jul 16, 2026, 15:37 Nikesh Arora Made Palo Alto Networks Cybersecurity’s Consolidator. Now He Has to Make the Stack Work as One

Jul 16, 2026, 13:40 Gukesh Dommaraju Became Chess's Youngest World Champion. Defending the Crown Is a Different Business

Jul 16, 2026, 10:35 Scott Wu Joined Devin With Windsurf. The Combined Product Must Earn a US$26 Billion Valuation

Person: Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw, Founder and Executive Chairperson of Biocon

Biocon Was Built for the Medicines Rich Markets Could Not Ignore

A FigureAsia examination of how Kiran Mazumdar-Shaw is positioning Biocon for the next phase of biotechnology.

Kiran Mazumdar-Shaw, Executive Chairperson of Biocon and Syngene International

Kiran Mazumdar-Shaw Has Recombined Biocon. The Biosimilars Bet Must Now Generate Cash

Biocon’s structure is finally catching up with the global biosimilars business Kiran Mazumdar-Shaw assembled. Stronger margins and falling leverage are encouraging, but dilution, price competition and manufacturing execution remain material tests.